PRESS RELEASE
News
-
-
PRESS RELEASE
Vior annonce la conversion des reçus de souscription et clôture de l’entente d’option de redevance avec Minière Osisko
Vior Inc. annonce la clôture du placement de 19,3 millions de dollars, la conversion des reçus de souscription en unités et la libération des fonds entiercés suite à l'accomplissement des conditions requises -
-
PRESS RELEASE
Custodian Property Income REIT plc: Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
Custodian Property Income REIT plc (CREI) announces transactions by Non-Executive Director and family members purchasing ordinary shares in the Company as per Market Abuse Regulations -
PRESS RELEASE
FSD Pharma, Inc. Wins Final Judgment to Confirm Arbitration Award of $3,059,998 Plus Interest Entered Against Dr. Raza Bokhari, Currently Serving as Chairman and CEO of Medicus Pharma Ltd.
FSD Pharma Inc. announces victory in legal battle against Dr. Raza Bokhari. Court judgment grants FSD Pharma damages and interest. Future plans detailed -
PRESS RELEASE
SouthGobi Announces Voting Results of Annual General Meeting; Appointment of Independent Non-Executive Director; Appointment of Lead Director; Change in Composition of Board Committees; And Dissolution of Operations Committee
SouthGobi Resources Ltd. announces voting results, appointment of directors, and dissolution of operations committee. Mr. Fan Keung Vic Choi elected as independent non-executive director -
PRESS RELEASE
Nagarro SE: Nagarro’s Annual General Meeting of June 27, 2024, passes all resolutions and appoints KPMG as auditor
Nagarro SE's Annual General Meeting on June 27, 2024, approves all resolutions and appoints KPMG as auditor. Details on the meeting outcomes and future dividend considerations -
-
-
PRESS RELEASE
EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Marketing Authorization Of Moderna’s RSV Vaccine, mRESVIA(R)
Moderna, Inc. receives positive opinion from EMA CHMP for mRESVIA mRNA-1345 vaccine for RSV in adults aged 60+. The decision from the European Commission is awaited
